When C. difficile is proven or suspected in symptomatic patients, use: metronidazole 400 mg (child: 10 mg/kg up to 400 mg) orally, 8-hourly for 7 to 10 days.
If intolerant of metronidazole, a course of oral bacitracin (20 000 to 25 000 units 6-hourly for 7 to 10 days) provides similar rates of symptomatic relief as metronidazole. However, the rate of clearance of both C. difficile toxin and culture is lower than for metronidazole and since there is no commercial preparation available, bacitracin must be prepared extemporaneously.

- The emergence of vancomycin resistance in enterococci makes it essential to reserve vancomycin for other severe infections unresponsive to other drugs. However, if unresponsive, relapsing or severe, oral vancomycin 125 mg (child: 3 mg/kg up to 125 mg) orally 6-hourly for 7 to 10 days may be necessary, and an infectious diseases physician or clinical microbiologist should be consulted.

- Control of hospital antibiotic use and infection control measures (additional contact precautions) are necessary to prevent nosocomial spread and outbreaks.

infection control issues

treatment

 In most cases of antibiotic-associated diarrhoea, no pathogen is identified.
 The first step is to cease treatment, if possible, with any antibiotic likely to be causing the symptoms. There is some evidence that prophylactic probiotics reduce the incidence of antibiotic-associated diarrhoea, but the appropriate combination of organisms has not been established and probiotics cannot be recommended for routine use.

- In immunocompromised patients, occasional cases of probiotic-associated bacteraemia have occurred.

general

risk

factors

pseudomembranous

colitis

- Clostridium difficile is responsible in a minority of cases of antibiotic-associated diarrhoea. C. difficile or its toxins can occasionally be demonstrated in infants, especially newborns, and some adults in the absence of symptoms, and treatment is unwarranted.

 Patient exposure to broad-spectrum cephalosporins, quinolones, lincosamides and some other broad-spectrum antibiotics (eg ticarcillin+clavulanate) is an important predisposing factor for C. difficile disease.